Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: A pilot study

Clinical Biochemistry

Volumn 41, Issue 14-15, 2008, Pages 1168-1174

  Anraku, Makoto ^a   Kitamura, Kenichiro ^a   Shintomo, Rina ^a   Takeuchi, Koji ^a   Ikeda, Hiroyuki ^a   Nagano, Junko ^a   Ko, Takehiro ^a   Mera, Katsumi ^a   Tomita, Kimio ^a   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Hemodialysis; Iron deficiency; Oxidative stress; Oxidized albumin; Renal anemia

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; BIOLOGICAL MARKER; CHONDROITIN SULFATE IRON; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; MALE; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FERRITINS; HEMATOCRIT; HEMOGLOBINS; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PILOT PROJECTS; RENAL DIALYSIS; SERUM ALBUMIN; TRANSFERRIN;

EID: 55649094184     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.07.007     Document Type: Article

References (33)

1. Fishbane S., and Maesaka J.K. Iron management in end-stage renal disease. Am J Kidney Dis 29 (1997) 319-333
2. Macdougall I.C., Chandler G., Elston O., and Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am. J. Kidney Dis 34 (1999) S40-S46
3. Mocks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta-a retrospective study. Nephron 86 (2000) 455-462
4. Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Its role in degradation of hyaluronic acid by a superoxide-generating system. FEBS Lett 96 (1978) 238-242
5. Rooyakkers T.M., Stroes E.S., Kooistra M.P., et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32 (2002) 9-16
6. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?. Semin Dial 17 (2004) 449-454
7. Singh U., and Jialal I. Oxidative stress and atherosclerosis. Pathophysiology 13 (2006) 129-142
8. Witko-Sarsat V., Gausson V., Nguyen A.T., et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 64 (2003) 82-91
9. Witko-Sarsat V., Gausson V., and Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins?. Kidney Int Suppl (2003) S11-S14
10. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49 (1996) 1304-1313
11. Odetti P., Garibaldi S., Gurreri G., Aragno I., Dapino D., Pronzato M.A., et al. Protein oxidation in hemodialysis and kidney transplantation. Metabolism 45 (1996) 1319-1322
12. Tovbin D., Mazor D., Vorobiov M., Chaimovitz C., and Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40 (2002) 1005-1012
13. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., and Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162 (2002) 221-225
14. Sogami M., Nagoka S., Era S., Honda M., and Noguchi K. Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 24 (1984) 96-103
15. Sogami M., Era S., Nagaoka S., et al. HPLC-studies on nonmercapt-mercapt conversion of human serum albumin. Int J Pept Protein Res 25 (1985) 398-402
16. Hayakawa A., Kuwata K., Era S., Sogami M., Shimonaka H., Yamamoto M., et al. Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B Biomed Sci Appl 698 (1997) 27-33
17. Sogami M., Era S., Nagaoka S., et al. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr 332 (1985) 19-27
18. Suzuki E., Yasuda K., Takeda N., et al. Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 18 (1992) 153-158
19. Soejima A., Kaneda F., Manno S., et al. Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kidney Dis 39 (2002) 1040-1046
20. Himmelfarb J., and McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60 (2001) 358-363
21. Lee Y., and Shacter E. Role of carbohydrates in oxidative modification of fibrinogen and other plasma proteins. Arch Biochem Biophys 321 (1995) 175-181
22. Shacter E., Williams J.A., Lim M., and Levine R.L. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 17 (1994) 429-437
23. Anraku M., Kitamura K., Shinohara A., et al. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 66 (2004) 841-848
24. Gejyo F., Saito A., Akizawa T., et al. 2004 Japanese Society for Dialysis Therapy Guidelines for Renal Anemia in Chronic Hemodialysis Patients. Ther Apher Dial 8 (2004) 443-459
25. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
26. Bartfay W.J., Butany J., Lehotay D.C., et al. A biochemical, histochemical, and electron microscopic study on the effects of iron-loading on the hearts of mice. Cardiovasc Pathol 8 (1999) 305-314
27. Feldman H.I., Santanna J., Guo W., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 (2002) 734-744
28. Drueke T., Witko-Sarsat V., Massy Z., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 (2002) 2212-2217
29. Yoshimura K., Nakano H., Yokoyama K., and Nakayama M. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. Clinical and Experimental Nephrology 9 (2005) 158-163
30. Maruyama Y., Nakayama M., Yoshimura K., et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2′-deoxyguanosine levels. Nephrol Dial Transplant. 22 (2007) 1407-1412
31. Witko-Sarsat V., Friedlander M.A., Nguyen Khoa T., et al. Advanced oxidation protein products (AOPP) as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 161 (1998) 2524-2532
32. Garneata L. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?. J Ren Nutr 18 (2008) 40-45
33. Worwood M. Serum ferritin. CRC Crit Rev Clin Lab Sci 10 (1979) 171-204